http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 12 Aug 2026 06:17:45 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+UBS/26908415.html UBS analyst Graham Doyle raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR56.00 (from EUR54.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+UBS/26908415.html Wed, 12 Aug 2026 06:17:45 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+UBS/26908415.html UBS analyst Graham Doyle raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR56.00 (from EUR54.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+UBS/26908415.html Wed, 12 Aug 2026 06:17:45 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+UBS/26908415.html UBS analyst Graham Doyle raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR56.00 (from EUR54.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+UBS/26908415.html Wed, 12 Aug 2026 06:17:45 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+UBS/26908415.html UBS analyst Graham Doyle raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR56.00 (from EUR54.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+UBS/26908415.html Wed, 12 Aug 2026 06:17:45 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR52+at+Morgan+Stanley/26893204.html Morgan Stanley analyst Aisyah Noor raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR52.00 (from EUR49.00) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR52+at+Morgan+Stanley/26893204.html Mon, 10 Aug 2026 04:52:19 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR52+at+Morgan+Stanley/26893204.html Morgan Stanley analyst Aisyah Noor raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR52.00 (from EUR49.00) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR52+at+Morgan+Stanley/26893204.html Mon, 10 Aug 2026 04:52:19 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR52+at+Morgan+Stanley/26893204.html Morgan Stanley analyst Aisyah Noor raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR52.00 (from EUR49.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR52+at+Morgan+Stanley/26893204.html Mon, 10 Aug 2026 04:52:19 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR52+at+Morgan+Stanley/26893204.html Morgan Stanley analyst Aisyah Noor raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR52.00 (from EUR49.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR52+at+Morgan+Stanley/26893204.html Mon, 10 Aug 2026 04:52:19 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+Deutsche+Bank/26879044.html Deutsche Bank analyst Falko Friedrichs raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR56.00 (from EUR55.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+Deutsche+Bank/26879044.html Thu, 06 Aug 2026 07:57:17 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+Deutsche+Bank/26879044.html Deutsche Bank analyst Falko Friedrichs raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR56.00 (from EUR55.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+Deutsche+Bank/26879044.html Thu, 06 Aug 2026 07:57:17 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+Deutsche+Bank/26879044.html Deutsche Bank analyst Falko Friedrichs raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR56.00 (from EUR55.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+Deutsche+Bank/26879044.html Thu, 06 Aug 2026 07:57:17 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+Deutsche+Bank/26879044.html Deutsche Bank analyst Falko Friedrichs raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR56.00 (from EUR55.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR56+at+Deutsche+Bank/26879044.html Thu, 06 Aug 2026 07:57:17 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR57.50+at+Barclays/26877040.html Barclays analyst Hassan Al-Wakeel raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR57.50 (from EUR56.50) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR57.50+at+Barclays/26877040.html Thu, 06 Aug 2026 04:55:39 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR57.50+at+Barclays/26877040.html Barclays analyst Hassan Al-Wakeel raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR57.50 (from EUR56.50) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR57.50+at+Barclays/26877040.html Thu, 06 Aug 2026 04:55:39 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR57.50+at+Barclays/26877040.html Barclays analyst Hassan Al-Wakeel raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR57.50 (from EUR56.50) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR57.50+at+Barclays/26877040.html Thu, 06 Aug 2026 04:55:39 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR57.50+at+Barclays/26877040.html Barclays analyst Hassan Al-Wakeel raised the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR57.50 (from EUR56.50) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Raised+to+EUR57.50+at+Barclays/26877040.html Thu, 06 Aug 2026 04:55:39 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Lowered+to+EUR55.20+at+JPMorgan/26877024.html JPMorgan analyst David Adlington lowered the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR55.20 (from EUR56.60) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Lowered+to+EUR55.20+at+JPMorgan/26877024.html Thu, 06 Aug 2026 04:38:24 -0400 FSNUY http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Lowered+to+EUR55.20+at+JPMorgan/26877024.html JPMorgan analyst David Adlington lowered the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR55.20 (from EUR56.60) while maintaining a Overweight rating. http://www.streetinsider.com/Intl+Ratings/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Lowered+to+EUR55.20+at+JPMorgan/26877024.html Thu, 06 Aug 2026 04:38:24 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Lowered+to+EUR55.20+at+JPMorgan/26877024.html JPMorgan analyst David Adlington lowered the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR55.20 (from EUR56.60) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Lowered+to+EUR55.20+at+JPMorgan/26877024.html Thu, 06 Aug 2026 04:38:24 -0400 FSNUY http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Lowered+to+EUR55.20+at+JPMorgan/26877024.html JPMorgan analyst David Adlington lowered the price target on Fresenius (FRE:GR) (OTC: FSNUY) to EUR55.20 (from EUR56.60) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Fresenius+%28FRE%3AGR%29+%28FSNUY%29+PT+Lowered+to+EUR55.20+at+JPMorgan/26877024.html Thu, 06 Aug 2026 04:38:24 -0400 FSNUY http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344 http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html <p>Fresenius Kabi, an operating company of Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar developed and manufactured by Dr. Reddy's Laboratories, referencing Rituxan® (rituximab).</p> <p>Under an exclusive commercialization agreement, Fresenius Kabi holds the rights to market the biosimilar in the United States, while Dr. Reddy's Laboratories developed, manufactured, and submitted the product for approval.</p> <p>Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It is used in the treatment of adults with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis.</p> <p>The FDA http://www.streetinsider.com/FDA/FDA+approves+rituximab+biosimilar+for+Fresenius+Kabi%27s+U.S.+portfolio/26857858.html Mon, 03 Aug 2026 16:09:13 -0400 A.06822034 A.37314791 A.50210934 FRE FSNUY O.00172650 O.00265012 O.00832529 O.20026344